Return to Clinical Trials Search Results

A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting

Primary The primary objective of this Phase 2 study is to evaluate the safety of Epcoritamab monotherapy without mandatory hospitalization for the first full dose of Epcoritamab in subjects with R/R DLBCL or R/R FL Grade 1-3a who have received at least 2 prior lines of systemic anti-lymphoma therapies including at least 1 anti-CD20 monoclonal antibody-containing therapy. Secondary The secondary objective of this Phase 2 study is preliminary assessment for overall safety and efficacy of monotherapy of epcoritamab in outpatient setting.

Primary The primary objective of this Phase 2 study is to evaluate the safety of Epcoritamab monotherapy without mandatory hospitalization for the first full dose of Epcoritamab in subjects with R/R DLBCL or R/R FL Grade 1-3a who have received at least 2 prior lines of systemic anti-lymphoma therapies including at least 1 anti-CD20 monoclonal antibody-containing therapy. Secondary The secondary objective of this Phase 2 study is preliminary assessment for overall safety and efficacy of monotherapy of epcoritamab in outpatient setting.